# Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration

> **NCT05893225** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University Hospital, Antwerp** · enrollment: 120 (estimated)

## Conditions studied

- Multiple Sclerosis
- Primary Progressive Multiple Sclerosis
- Secondary-progressive Multiple Sclerosis

## Interventions

- **DRUG:** Metformin Hydrochloride 850 mg Oral Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05893225
- **Lead sponsor:** University Hospital, Antwerp
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-23
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-02-28
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-06-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05893225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05893225, "Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05893225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*